IDH1 and colorectal carcinoma: Furthermore, despite IDH1/2 mutations detected in the “neo RAS wt” patients have been recently reported as potential trunk drivers suitable for targeted therapy in CRC (23), further studies are needed to understand their potential clinical significance.